Category: BridgeBio

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as its eyes an…

BridgeBio has vaulted over the success bar it set for a phase 3 rare disease trial, linking the candidate to significant improvements on biomarker and clinical outcomes to tee up…